1.5 mg semaglutide 5mg | GLP-1 Research Peptide Semaglutide / Cyanocobalamin Injection |

There was no increased risk for hypoglycemia in the lixisenatide group

Phase 2 trials investigated once-weekly subcutaneous doses ranging from 1 mg to 12 mg, administered via a gradual escalation schedule

Our team of drug injury attorneys and class action lawyers is investigating potential GLP-1 NAION eye injury lawsuit cases and settlement claims of individuals who were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) and suffered sudden vision loss, blindness, optic nerve damage or other eye injury after using Ozempic or other GLP-1 receptor agonist medications

Our clinical team includes Aesthetic Injectors Rebecca Fant, MSN, FNP-C and Angela Hunsaker, RN

One of the key areas of focus has been its effectiveness in skincare products, where it has demonstrated remarkable anti-aging properties

Although we dont see increases in the rate of first-time prescriptions overall, all populations over the age of 30 experienced significant increases in the rate of first-time prescriptions